MAPT and Alzheimer disease: In the patent “Use of gambierol for treating and/or preventing neurodegenerative diseases related to tau and beta-amyloid”, filed in 2012 by Botana et al. [89], it is mentioned that in AD, the potassium channels, specifically the kV3.1 channels, are diminished, and in the examples provided in the patent, surprisingly, gambierol produces the blockage thereof despite being useful for the reduction of both the overexpression of β-amyloid and the hyperphosphorylation of tau proteins.